Literature DB >> 7696722

Delayed neutropenia with ticlopidine.

D K Farver1, L A Hansen.   

Abstract

OBJECTIVE: To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug. CASE
SUMMARY: A 68-year-old woman was placed on ticlopidine after a transient ischemic attack. Ten days later the drug was discontinued because the patient developed a rash. Eighteen days later she developed pneumonia and neutropenia, which were believed to be induced by ticlopidine. DISCUSSION: Drug-induced neutropenia is serious and at times life-threatening. Ticlopidine-induced neutropenia has been described in patients receiving the medication. We report neutropenia occurring 18 days after discontinuation of ticlopidine.
CONCLUSIONS: Indications for prescribing ticlopidine must be closely followed. Complete blood cell count monitoring is imperative while the patient is receiving the medication. This case suggests that the duration of monitoring after the discontinuation of ticlopidine may need to be longer than the 14 days recommended by the manufacturer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7696722     DOI: 10.1177/106002809402801203

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.

Authors:  F L Paradiso-Hardy; C M Angelo; K L Lanctôt; E A Cohen
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

Review 2.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

Review 3.  Adverse haematological effects of ticlopidine. Prevention, recognition and management.

Authors:  B B Love; J Biller; M Gent
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.